Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test Product E Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 22, 2026, 4:08 PM EDT
Not listed Phase 2 Interventional

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

NCT02173223
View directory record Official record
Conditions
Advanced Glaucoma
Interventions
Rho-Kinase Inhibitor
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 22, 2026, 4:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Tazemetostat
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Derby, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Arterial Inflammation and E-Cigarettes

NCT02734888
View directory record Official record
Conditions
Arterial Inflammation
Interventions
No drug or device, only a test. The test is called a PET/CT
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD210202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems

NCT04751461
View directory record Official record
Conditions
Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
Interventions
Product A, Product B, Product C, Product D, Product E
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes

NCT02416011
View directory record Official record
Conditions
Smoking Cessation
Interventions
GENERIC, eTARGET
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Sep 22, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

NCT03166787
View directory record Official record
Conditions
Smoking, Endothelial Dysfunction
Interventions
Charcoal hookah, E-coal hookah, Cigarette, Carbon Monoxide inhalation, Room Air inhalation, vitamin C, tadalafil
Other · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assist MH Digital Technologies to Support School Mental Health Care

NCT06728683
View directory record Official record
Conditions
Mental Health Strategies, School Mental Health Services, Digital Technologies, Technology Development
Interventions
ASSIST-MH
Other
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Evaluation of Laparoscopic Hysterectomy Simulator

NCT02234856
View directory record Official record
Conditions
Evaluation of Laparoscopic Hysterectomy Simulator
Interventions
Laparoscopic Hysterectomy trainer
Procedure
Lead sponsor
Unity Health Toronto
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 22, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional

ONC201 in Pediatric H3 K27M Gliomas

NCT03416530
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

NCT05026658
View directory record Official record
Conditions
Digital Acuity Product
Interventions
Visibly Digital Acuity Product
Device
Lead sponsor
Visibly
Industry
Eligibility
22 Years to 40 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Shelby, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents (smokeScreen)

NCT03722888
View directory record Official record
Conditions
Smoking
Interventions
smokeSCREEN video game
Device
Lead sponsor
Yale University
Other
Eligibility
11 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hamden, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 22, 2026, 4:08 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 22, 2026, 4:08 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotine Pouch Pharmacokinetics Abuse Liability

NCT07476144
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
Drug
Lead sponsor
JT International SA
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Results available

E-health Implementation (Iowa)

NCT03954184
View directory record Official record
Conditions
Substance Use Disorders
Interventions
NIATx-TI with Product Training/On-line Support
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
23,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Adel, Iowa • Algona, Iowa • Ames, Iowa + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Mobile Technology and Online Tools to Improve Asthma Control in Adolescents - Usability

NCT02816216
View directory record Official record
Conditions
Asthma
Interventions
CampAir
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 22, 2026, 4:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 22, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modern Nicotine Oral Product Abuse Liability

NCT06777784
View directory record Official record
Conditions
Smoking, Tobacco Use
Interventions
Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product N
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lexington, Kentucky • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 22, 2026, 4:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 22, 2026, 4:08 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

NCT05419297
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 22, 2026, 4:08 PM EDT